Moderna and Pfizer, the two leading companies in vaccine development are hoping to get their COVID-19 vaccine trial results in a few weeks. A few ticker tests are in the final stages.
The world is hoping for a COVID-19 tick. Now waiting for the results. COVID-19 vaccination in the United States and Europe is on the rise, raising hopes of getting the COVID-19 vaccine by December. The news agency AFP reported this information.
In addition to the Moderna and Pfizer vaccines, there is also hope for the Oxford and Estrogen Gene vaccines. The vaccine has shown resistance in adults and young people, the researchers said.
Experts say vaccination work is progressing at a great pace. Where it takes 10 to 15 years to make a vaccine, it is expected to be available in the market quickly. However, the UK Vaccine Task Force has expressed skepticism, saying first-generation vaccines may not be equally effective for everyone.
According to the World Health Organization, more than 150 vaccines are now being developed around the world. Of these, 44 ticker clinical trials are underway. 11 vaccines are in the final stages of testing.
The US pharmaceutical company Pfizer had earlier said it would know the results of the COVID-19 ticker by October. But now they have expressed hope that the results of their vaccination could be known within this year.
Officials at the organization hope that if the vaccine test goes well and the vaccine is approved, they will be able to supply 40 million doses of the vaccine in the United States. Albert Borla, Pfizer’s chief executive officer (CEO), said the approval of the vaccine depended on a number of factors. This includes knowing the effectiveness of the tick.
“We have reached the final stage,” Borla told AFP. If all goes well, we will be ready to provide the initial dose.
Borla expressed moderate optimism about the possibility of providing coronavirus vaccine within this year. He says Pfizer has not yet reached key criteria in evaluating the effectiveness of the vaccine. They are considering applying for emergency approval of the vaccine in the third week of November.